Showing results (21-30 of 108) with videos related to
Sort By:
Pageof 11
Current Medical Research and Opinion|August 12, 2020
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated <i>EGFR</i>-mutated metastatic non-small-cell lung cancerKiyotaka Yoh, Shinji Atagi, Martin Reck, et al.Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effectiveAlvaro Quintanal-Villalonga, Sonia Molina-Pinelo, Patricia Yagüe, et al.Eclinicalmedicine|January 11, 2024
Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)Daneng Li, Yohann Loriot, Adam M Burgoyne, et al.Clinical Lung Cancer|November 30, 2016
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung CancerEdward B Garon, Martin Reck, Luis Paz-Ares, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2026
Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung CancerBenedetta Del Rio, Silvia Masini, Camilo Cáceres-Galvis, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2019
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved EfficacyAlvaro Quintanal-Villalonga, Sonia Molina-Pinelo, Cristina Cirauqui, et al.Clinical Lung Cancer|January 11, 2018
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib ResultsMartin Reck, Edward B Garon, Luis Paz-Ares, et al.JTO Clinical and Research Reports|September 30, 2021
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)Rathi N Pillai, Suresh S Ramalingam, Meena Thayu, et al.Clinical Lung Cancer|March 26, 2017
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage DiseaseMark A Socinski, Frederic J Kaye, David R Spigel, et al.European Journal of Cancer (Oxford, England : 1990)|May 13, 2023
Profile and outcome of cancer patients enrolled in contemporary phase I trialsEmily Alouani, Anas Gazzah, Sandrine Mercier, et al.Pageof 11